Search Results - "Petracci, Fernando E."

Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates by González-Hurtado, Daniel, Rivero, Sergio, Samamé Pérez-Vargas, Juan Carlos, Petracci, Fernando E.

“…Prognostic and predictive factors for early and late distant distance recurrence risk in estrogen-receptor positive and HER2-receptor negative early breast…”
Get full text

The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review by Narvaez, Dana, Nadal, Jorge, Nervo, Adrian, Costanzo, María Victoria, Paletta, Claudio, Petracci, Fernando E, Rivero, Sergio, Ostinelli, Alexis, Freile, Berenice, Enrico, Diego, Pombo, Maria Teresa, Amat, Mora, Aguirre, Edgar Danilo, Chacon, Matias, Waisberg, Federico

“…This narrative review aims to clarify the role of tertiary lymphoid structures in breast cancer. We examine their development, composition, and prognostic…”
Get full text

Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2 by Narváez, Dana, Waisberg, Federico, Soule, Tomas, Angel, Martín, Bruno, Luisina, Girotti, Maria Romina, Pupareli, Carmen, Chacón, Matías, Petracci, Fernando E

“…BackgroundNext-generation sequencing (NGS) has proven to be a key implementation to understanding biological pathways involved in cancer. In daily practice,…”
Get full text

LuciA-15 - a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and/or somatic mutation of BRCA genes or homologous recombination repair related genes by Petracci, Fernando E, Villarreal-Garza, Cynthia, Argañaraz, Facundo, Abuin, Gonzalo Gómez, Peñaloza, José, Flores, Marcos Ariel, Piazzoni, Luciano, Riggi, Cecilia, Fabiano, Lucía, González, Lucía, Cieplinski, Belén, Rivero, Sergio, Korbenfeld, Ernesto, Mandó, Pablo

“…Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) improve progression free survival among patients with HER2 negative (HER2-ve) advanced breast…”
Get full text

Abstract PO1-16-06: LuciA-15 - A real-world prospective study of PARP inhibitors for the treatment of Latin American patients with HER-2 negative metastatic breast cancer with mutation of BRCA1/2 genes or in the Homologous Recombination Repair genes by Petracci, Fernando E., Villarreal-Garza, Cynthia, Argañaraz, Facundo, Abuin, Gonzalo Gómez, Peñaloza, José, Flores, Marcos A., Piazzoni, Luciano, Riggi, Cecilia, Fabiano, Lucía, González, Lucía, Cieplinski, Belén, Rivero, Sergio, Korbenfeld, Ernesto, Mandó, Pablo

“…Abstract Background PARP inhibitors (PARPi) improves progression free survival among patients with HER2 negative (HER2-ve) advanced breast cancer (ABC) and a…”
Get full text

Abstract PO5-02-03: Does the recommendation of adjuvant CDK4/6 inhibitors implicate more ovarian suppression in premenopausal patients? A real-world study of a public and a private Argentinean institution by Lopez, Vanesa, Narvaez, Dana, Nadal, Jorge, Waisberg, Federico, Nervo, Adrian, Costanzo, Victoria, Paletta, Claudio, Petracci, Fernando E., Rivero, Sergio, Ostinelli, Alexis, Chacón, Matías, Aguilar, Andrea, Kuzminin, Alejandro, Nico, Ageles, Rovera, Evelina, Kassis, Naima, Camaño, Maria Zapata, Almada, Carolina, Savignano, Maria, Roganovich, Gustavo, Azar, Maria Eugenia, Caceres, Valeria

“…Abstract Introduction The recently published NATALEE trial has reported an increase of invasive disease free survival with the addition of ribociclib to…”
Get full text

Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2 by Narváez, Dana, Waisberg, Federico, Soulé, Tomás, Angel, Martín, Bruno, Luisina, Girotti, Maria Romina, Pupareli, Carmen, Chacón, Matías, Petracci, Fernando E

“…BackgroundNext-generation sequencing (NGS) has proven to be a key implementation to understanding biological pathways involved in cancer. In daily practice,…”
Get full text